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Abstract
Background: 5HT1A agonists have previously been shown to promote recovery in animal models
of stroke using ex vivo outcome measures which have raised the hopes for a potential clinical
implementation. The purpose of this study was to evaluate the potential neuroprotective
properties of a novel 5HT1A agonist DU123015 in 2 different models of transient focal ischaemic
stroke of varying severities using both in vivo neuroimaging and behavioural techniques as primary
outcome measures. For these studies, the NMDA receptor antagonist MK-801 was also utilized as
a positive control to further assess the effectiveness of the stroke models and techniques used.
Results: In contrast to MK-801, no significant therapeutic effect of DU123015 on lesion volume
in either the distal MCAo or intraluminal thread model of stroke was found. MK-801 significantly
reduced lesion volume in both models; the mild distal MCAo condition (60 min ischaemia) and the
intraluminal thread model, although it had no significant impact upon the lesion size in the severe
distal MCAo condition (120 min ischaemia). These therapeutic effects on lesion size were mirrored
on a behavioural test for sensory neglect and neurological deficit score in the intraluminal thread
model.
Conclusion: This study highlights the need for a thorough experimental design to test novel
neuroprotective compounds in experimental stroke investigations incorporating: a positive
reference compound, different models of focal ischaemia, varying the duration of ischaemia, and
objective in vivo assessments within a single study. This procedure will help us to minimise the
translation of less efficacious compounds.
Background
Although the neurological consequences of stroke dam-
age remain a leading cause of adult disability in industr-
ialised countries [1], little progress has been achieved in
translating promising experimental therapies into clinical
practice. This lack of translational success has been thor-
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development for stroke has been the investigation of neu-
roprotective compounds capable of protecting potentially
salvageable neurons from ischaemic cell death. These
potential neuroprotective compounds have, in the main,
been successful in pre-clinical studies, but all bar an
exceptional few have failed during early clinical trials, this
being mostly due to lack of efficacy and potential adverse
effects [3]. However, with an aging population and an
increasing socioeconomic burden of stroke the persistent
quest for potential neuroprotective agents is an absolute
necessity [4].
One of the neuroprotective targets currently under inves-
tigation is the 5-hydroxytryptamine (5-HT) system, which
includes 5HT1A receptor agonists. These compounds have
been demonstrated to stimulate postsynaptic 5HT1A
receptors located on the hippocampus and neocortex
which are both vulnerable areas following ischaemia
[5,6]. The activation of these receptors has been hypothe-
sised to offset the excitotoxic properties of glutamate [7].
This is attributable to the hyperpolarisation of neuronal
cells due to the activation of inwardly rectifying potas-
sium channels [5]. 5HT1A agonists (e.g. Repinotan) have
therefore been evaluated in models of ischaemic injury
and have demonstrated substantial neuroprotective prop-
erties in both in vitro [8] and in vivo pre-clinical assess-
ments [9-12]. However, these investigations have not
included translatable in vivo measures of lesion severity,
such as magnetic resonance imaging (MRI), or a direct
comparison of efficacy in multiple models of cerebral
ischaemia.
We here present a detailed in vivo investigation of the
potential neuroprotective properties of a novel 5HT1A ago-
nist, DU123015, for the treatment of transient focal cere-
bral ischaemia. For this, 2 animal models of ischaemia
with varying occlusion times, different rodent strains,
structural and behavioural outcome measures, and acute
and sub-acute time-points are compared for the 5HT1A
agonist in addition to a positive control compound (MK-
801) that is known to be neuroprotective.
Methods
All procedures were performed in accordance with the UK
Animals (Scientific Procedures) Act of 1986 and the Ethi-
cal Review Panel of Queen Mary, University of London.
All animals were acclimatised to their housing conditions
for at least a week prior to the commencement of the
study. Food and water were available ad libitum.
Middle Cerebral Artery occlusion (MCAo)
Distal MCAo model
The surgical procedure was performed as described by
Buchan et al. (1992). Briefly, adult male spontaneously
hypertensive rats (SHR's, 200–250 g, Charles River, UK)
were anaesthetised with 2% isofluorane in a mixture of
30% O2 and 70% N2O. Body temperature was monitored
and maintained at 37°C using a heating blanket and rec-
tal probe. O2 saturation was constantly above 95% satura-
tion during the surgical procedure and heart rate
remained within the correct margins of 380–420 bpm.
The rat was positioned onto its left flank. An incision was
then made between the right external auditory canal and
the cantus of the eye. A burr hole was then drilled into the
skull at the position where the zygomatic arch meets the
squamozal bone to expose the right MCA. The dura was
cut and retracted to expose the MCA which was then
occluded with a number 1 microclip (Codman, Boston,
Mass) placed proximally to the point where the MCA
crosses the supracerbral vein in the rhinnal fissure. Imme-
diately following the occlusion, the right CCA was
occluded in order to reduce anterograde arterial perfusion
[13]. The animals then regained consciousness during
MCA occlusion before being reanaesthetized for reper-
fusion. All animals were monitored and weighed daily
and a standardized post-operative care regime was imple-
mented [14]. Animals were fed a moistened diet of breed-
ing pellets and baby food (Heinz, UK) to facilitate food
consumption and avoid weight loss. If weight loss did
occur, animals were given a 5 ml Duphalyte and saline
(50:50) injection i.p. daily for physiological support and
to facilitate weight gain.
Intra-luminal thread model of MCAo
Male Sprague Dawley rats (280–360 g, Charles River, UK)
were anaesthetised with 2% isoflurane in a mixture of
30% O2 and 70% N2O. Body temperature, O2 saturation
and heart rate were all monitored as described above. The
animals were then subjected to a 90 minutes MCAo using
an adapted version of the method originally described by
Koizumi et al. (1986) [15]. Briefly, an incision was made
through the midline to expose the right common carotid
artery. A 4-0 monofilament nylon suture with a silicone
rubber coated 0.31 mm diameter tip was placed into the
internal carotid artery via an external carotid arteriotomy
and advanced approximately 21 mm from its original
position to obstruct the blood flow to the MCA. The ani-
mals were allowed to fully recover from anaesthesia dur-
ing the MCAo. Following 90 minutes of MCA occlusion,
the animals were re-anaesthetized and the filament was
retracted completely to allow reperfusion of the MCA.
Neurological Score
A previously described battery of neurological tests com-
prising the grasping reflex (ability to grasp with both
hands simultaneously), placing reaction, visual placing,
righting reflex, tilted cage top test, horizontal bar test,
spontaneous motility, circling and the tail lift test were
conducted daily [14]. Each test was awarded either a zero
for successful completion or a one indicating a neurolog-
ical deficit. Therefore, the higher the overall score, thePage 2 of 12
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Kruskall-Wallis test was used for statistical analysis.
Drug Preparation and administration
Animals were selected randomly from the cage and group
assignment was alternated to yield the same number of
animals in each group for any given day of surgery.
DU123015
DU123015 (European patent number: EP 0 650 964 A1)
has a plasma half life of 0.7 – 1 hr. DU123015 is a selec-
tive 5-HT1A receptor agonist (pKi = 9.2) and has at least a
100 fold selectivity over other targets, e.g. 5-HT1D (pKi =
7.2). Receptor binding studies indicate that no binding
(pKi < 6) was observed at other GPCRs, transporters or
ion-channel targets. The putative nature of an interaction
with the 5-HT1A receptor demonstrated that DU123015
was a full 5-HT1A agonist with a pEC50 of 8.0. Induction
of the 5-HT1A behavioural syndrome was observed at 0.1
mg/kg i.v. EEG recordings demonstrating that total energy
was reduced following DU123015 administration illus-
trating the compounds ability to penetrate the blood
brain barrier and have an effect on global cortical brain
function [See additional file 1].
A stock solution of DU123015 (Solvay Pharmaceuticals,
Netherlands), was prepared daily at 4.4 mg/ml using ster-
ile water by an experimenter that was not involved in the
administration of the compound. For i.v. administration,
an infusate of 4.4 μg/ml solution was prepared from the
stock solution with 5% glucosaline. To evaluate the neu-
roprotective properties of DU123015, it was firstly admin-
istered as an intravenous bolus [35.2 μg/kg] immediately
after the start of MCA occlusion. Following this bolus,
DU123015 was continuously infused intravenously (i.v.)
at a concentration of 8.8 μg/kg/hr i.v. for 4 hours in fully
conscious rats at a rate of 0.5 ml/hour. This dose and route
of administration is comparable to other agonists with a
similar affinity and potency on the 5HT1A receptor
[12,16,17]. The femoral vein was used for i.v. drug infu-
sion using polyethylene tubing (ID 0.58 mm and OD 0.96
mm) which was inserted prior to MCA occlusion. A long
catheter was used which was buried under the skin and
exited at the back of the neck. This was attached to a swivel
arrangement to permit continuous i.v. infusion of the
drug to the conscious rat via an infusion pump. Control
animals received an intravenous bolus loading dose of 5%
glucosaline (Baxter, UK) at occlusion followed by a 4 hour
continuous infusion of 5% glucosaline at the same infu-
sion rate as DU123015 (i.e. 0.5 ml/hr).
MK-801
Dizocilpine (+)-MK-801 maleate salt (Sigma-Aldrich, UK)
was dissolved daily in saline and administered intra-peri-
toneally (i.p.) as a bolus at a concentration of 1.5 mg/kg
at occlusion. An i.p. 0.9% saline bolus injection served as
a control.
Magnetic Resonance Imaging
Acquisition
Magnetic Resonance Imaging was performed on a 4.7T
Varian horizontal bore NMR spectrometer. A quadrature
birdcage coil with a 63 mm internal diameter (Varian,
USA) was used for RF transmission and reception. T2-
weighted images (TE = 60 ms; TR = 2800 ms) were
acquired for each animal at each time point [See addi-
tional file 2]. Total scanning time was 1 hour. The images
were collected with a data matrix size of 192 × 192 over a
field of view of 3.5 × 3.5 cm, yielding an in plane resolu-
tion of 182 μm with 40 contiguous 450 μm thick slices
and six signal averages per phase encoding step.
Induction of anaesthesia consisted of 4% isofluorane in a
mixture of 30% O2 and 70% N2O for approximately 5
minutes. Isofluorane concentration was then reduced to
1.5% and maintained at this concentration for the dura-
tion of MR image acquisition. Both respiration and heart
rate were monitored during the scanning process as well
as blood oxygen saturation using a pulse oximeter. Body
temperature was monitored and maintained at 37°C with
a heated blanket and feedback rectal temperature probe.
Post-processing of MRI
Absolute lesion and brain volumes were measured by
converting voxel values into mm3. To account for individ-
ual differences in brain size, total brain volume was meas-
ured to determine % lesion over the entire brain. Lesion
volumes were obtained using a semi-automated threshold
process whereby the mean signal intensity in the cortex of
the unaffected contralateral hemisphere was considered as
a reference value to determine infarcted tissue [18]. The
lesion was then delineated further using a semi-auto-
mated contouring system to discard hyperintensities ema-
nating from the cerebral ventricles. To establish
neuroprotection in relation to the control group, the
mean volume of the control group was set at 100% to cal-
culate the degree of infarct reduction in the respective
treatment group. A GLM repeated measures ANOVA was
then performed to detect any overall differences between
the groups. A one way ANOVA was then also performed
in order to identify differences between the groups at each
time-point.
Inclusion/Exclusion criteria
Distal MCAo
Two different criteria were applied for the exclusion of
animals with a lesion using this method of MCAo; 1. Ani-
mals with no apparent lesion observed on the MRI scan at
day 1 as a result of the clip were excluded from the study;
2. The remaining animals were then further screenedPage 3 of 12
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(Graphpad software Inc.) of detecting an outlier in order
to remove unrepresentative animals
Intraluminal thread
Additionally to the 2 exclusion criteria for distal MCAO,
animals that presented with a sub-arachnoid haemor-
rhage as observed by MRI on day 1 were also excluded
from further analysis.
The application of exclusion criteria was applied whilst
the experimenter remained blinded to treatment alloca-
tion. An overview of animals that were excluded in each
condition are summarised in Table 1.
Statistical analysis
Group size was determined based on a power calculation
previously described in Ashioti et al. (2007). All statistical
analyses were performed using the Statistical Package for
Social Science (SPSS version 13). A GLM repeated meas-
ures ANOVA was performed on all MRI and bilateral
asymmetry test data to detect overall differences between
groups. This was followed by a one-way ANOVA to
observe any differences at each individual time-point. A
non-parametric Kruskall-Wallis test was performed on all
neurological scoring data to detect differences between
groups at each time-point. All MRI and bilateral asymme-
try test and neurological scoring data are expressed as
mean ± SEM. A P value of less than 0.05 was chosen as the
significance level for all analyses.
Experiment 1: Neuroprotection in an extensive distal 
MCAo lesion
Animals and Design
A 120 minutes distal MCA occlusion generated an exten-
sive, but very consistent cortical lesion to probe neuropro-
tection [13]. As described above, SHR rats were occluded
120 minutes using the distal transient MCAo model to
induce extensive damage to the cortex without affecting
subcortical structures. This was measured 1 and 3 days fol-
lowing infarction by MRI. As previously reported, this
model also induces a very consistent neurological deficit
that is strongly correlated to the extent of damage [13]. To
determine if neuroprotection can be achieved under these
conditions, a separate cohort of animals received the
NMDA antagonist MK-801 as a positive control.
Experiment 2: Neuroprotection in a mild distal MCAo 
lesion
Animals and Design
As prolonged focal ischaemia can diminish penumbral
areas of 'tissue at risk', assessment of efficacy in a milder
lesion model is therefore also necessary to determine
potential neuroprotective effects under these conditions.
A mild distal MCAo lesion induced by 60 minutes tran-
sient cerebral ischaemia in the distal MCAo model pro-
vides these conditions [13]. Evaluation of structural
damage on day 1 and 3 by MRI and daily neurological def-
icits afforded a reliable assessment of acute neuroprotec-
tive effects. To establish the degree of potential
neuroprotection under these conditions, the reference
compound MK-801 was included as a positive control in
a separate cohort of animals.
Experiment 3: Efficacy in a combined cortical and sub-
cortical infarct
Animals and Design
To ensure that neuroprotective effects are not model spe-
cific, potential therapeutic efficacy requires assessment in
a second model of focal ischaemia (STAIR, 1999). Addi-
tionally, a longer assessment frame can provide a more
extensive investigation of potentially delayed neuropro-
tective effects. Animals therefore underwent MRI scanning
on day 1, 7 and 14 with concomitant behavioural assess-
Table 1: Summary of the included and excluded animals for each condition.
Model Inclusion/Exclusion DU123015 MK-801
Drug Control Drug Control
Experiment 1
120 minutes
Enrolled 8 10 9 7
No Lesion 1 2 3 2
Outlier 1 1 0 0
Included 6 7 6 5
Experiment 2
60 minutes
Enrolled 10 18 13 12
No Lesion 2 7 4 4
Outlier 0 0 0 0
Included 8 11 9 8
Experiment 3
ILT
Enrolled 12 15 8 13
No Lesion 0 3 2 2
Haemorrhage 1 2 1 6
Outlier 0 0 0 0
Included 11 10 5 5Page 4 of 12
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daily neurological scoring. The reference compound MK-
801 was investigated as a positive control in a separate
cohort of animals.
Bilateral Asymmetry Test (BAT)
For this, sticky tape (Dudley, UK) approximately 6 cm
long and 0.5 cm wide was placed around both forepaws
of the animal [14]. The animals were then placed within a
holding cage and the latency in seconds to remove the
strips of tape from both forepaws was recorded. Two trials
per animal, alternating the order of tape application, i.e.
right versus left, were recorded for each time point. Ani-
mals were assessed prior to MCAo surgery (-2 days) to
provide a baseline measure and at 3 and 14 days post-
treatment to evaluate the potential behavioural effects of
neuroprotection. For statistical analyses, a GLM repeated
measures ANOVA was calculated to establish a main
group effect. This was followed by one-way ANOVAs to
determine differences at each time-point.
Results
Experiment 1: Neuroprotection in a extensive distal MCAo 
lesion
As a general indication of recovery, post-operative weight
was recorded daily. In both DU123015 and glucosaline
control-treated groups, post-operative weight did not
appear to alter greatly from the pre-operative weight (Fig-
ure 1A). This was also observed in the MK-801 treated and
saline treated control groups (Figure 1B) indicating that
neither compound exerted any deleterious effect on post-
operative recovery. Neurological scoring assesses the
impact of damage on neurological functions to provide a
basic evaluation of functional impairments and potential
minimisation of deficits by neuroprotection. DU123015
treated and control animals exhibited a mild neurological
deficit (score of 3.5) that remained stable over the first 3
days post-surgery (Figure 1C). However, there was no sig-
nificant difference between DU123015 and glucosaline-
treated animals. Likewise, no significant difference
between MK-801 treated and control animals was
detected on the neurological scale (Figure 1D).
Differences in infarct volume were assessed using a GLM
repeated measures ANOVA which indicated that
DU123015 did not significantly impact on the overall vol-
ume of the 120 minutes ischaemic lesion compared to
controls at either 1 or 3 days. The infarct volume of the
DU123015 treated group increased by 8% ± 5 at day 1 and
by 10% ± 4 at day 3 compared to controls. This indicates
a minor exacerbation of the lesion due to the presence of
the DU123015 compound. However, this was not statisti-
cally significant (F(1,11) = 1.505, P = 0.245) (Figure 1E).
The use of MK-801 as a positive control in this study also
did not decrease infarct volume compared to its controls.
No significant difference in infarct volume between MK-
801 treated and control animals was observed (F(1,9) =
1.206, P = 0.301) (Figure 1F).
Experiment 2: Neuroprotection in a mild distal MCAo 
lesion
The body weight of both DU123015-treated and its con-
trol group was stable across time and did not change from
baseline body weight (Figure 2A). Likewise, no detrimen-
tal impact of surgery or treatment was detected in the MK-
801-treated group when compared with control animals
(F(1,15) = 0.824, P = 0.378, Figure 2B). All animals exhib-
ited neurological deficits. However, a Kruskal-Wallis non-
parametric test revealed no significant difference between
DU123015 and control treated animals (Figure 2C). The
MK-801 treated animals performed better at neurological
tasks than their respective controls at all time-points post-
surgery. Although there is no significant difference in neu-
rological deficits between MK-801 and control-treated
animals, a Kruskal-Wallis test indicates a borderline sig-
nificant improvement after MK-801 treatment on day 2 (P
= 0.056) (Figure 2D).
Hyperintense regions were detected within the cortex in
T2-weighted MRI images at both 1 and 3 days post MCAo.
A GLM repeated measures ANOVA revealed no significant
differences between the lesion volumes of the DU123015
treated animals and control animals (F(1,17) = 2.304, P =
0.147). A power calculation was also performed on this
data and revealed that the number of animals required
within each group to reach a statistical significant differ-
ence is 35. This number is too large for pre-clinical exper-
iments and it was therefore deemed as unethical to
reinvestigate DU123015 in this model (Figure 2E). How-
ever, in comparison MK-801 significantly reduces infarct
size by 62% ± 12 1 day post surgery and 56% ± 11 3 days
post-surgery (F(1,15) = 7.496, P < 0.05). A one-way ANOVA
further revealed that the MK-801 treated group is signifi-
cantly different from controls at both time-points post-
occlusion (day 1 P < 0.05, day 3 P < 0.05, Figure 2F).
Experiment 3: Effect of DU123015 on a combined cortical 
and sub-cortical infarct
The intraluminal thread model has a greater impact on the
animals' general physiology and this is reflected in the
greater weight loss and time to recover to pre-operative
weight. The maximum weight loss for both the
DU123015-treated animals and controls was observed on
days 2 to 4 (Figure 3A). However, pre-operative weight
recovered by 14 days post-surgery. An independent t test
revealed a significant difference in pre-operative weight
between DU123015 and placebo treated groups (P <
0.05). However, A GLM repeated measures ANOVA
revealed no significant differences between the weights of
DU123015-treated animals and their respective controlsPage 5 of 12
(page number not for citation purposes)
BMC Neuroscience 2009, 10:82 http://www.biomedcentral.com/1471-2202/10/82
Page 6 of 12
(page number not for citation purposes)
Neuroprotective efficacy of 5HT1A agonist DU123015 and positive control MK-801 in the 120 minutes distal MCAo modelFig re 1
Neuroprotective efficacy of 5HT1A agonist DU123015 and positive control MK-801 in the 120 minutes distal 
MCAo model. The body weights (absolute weight in grams ± SEM) did not differ significantly for DU123015- (A) or MK-801-
treated subjects (B). (C) No significant differences on neurological deficit were found for DU123015- (D) or MK-801-treated 
animals (E). No significant differences between groups were observed for oedema corrected MRI lesion volumes for 
DU123015-treated animals and glucosaline control treated animals (F). Also, no significant reduction in lesions was detected 
using the positive control compound MK-801.
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Neuroprotective efficacy of the 5HT1A agonist DU123015 and positive control MK-801 in the 60 minutes distal MCAo modelFig re 2
Neuroprotective efficacy of the 5HT1A agonist DU123015 and positive control MK-801 in the 60 minutes dis-
tal MCAo model. (A) The body weights of animals treated with DU123015 and glucosaline-treated controls. No significant 
differences between groups were observed. (B) The body weights for MK-801 and saline-treated controls. No significant differ-
ences between groups were observed. Neither DU123015 (C), nor MK-801 (D), significantly improve neurological functions, 
although on day 2 MK-801 almost significantly improved function (P = 0.056). (E) Oedema corrected MRI lesion volumes did 
not differ for DU123015-treated animals and glucosaline controls. (F) MK-801-treated animals exhibited a significant reduction 
in lesion volume at both time-points. (**) P < 0.01, (*) P < 0.05.
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BMC Neuroscience 2009, 10:82 http://www.biomedcentral.com/1471-2202/10/82at all other time-points (F(1,19) = 2.069, n.s.). MK-801
showed an improved weight gain from 1 to 2 weeks post-
surgery compared to controls, although this did not reach
statistical significance (Figure 3B, F(1,8) = 0.566, P =
0.473). All animals recovered to pre-operative weight
between day 9 and day 10. Treating animals with MK-801
or DU123015 therefore did not significantly accelerate
recovery of pre-operative weights.
DU123015 did also not significantly improve the ani-
mals' neurological deficits at any time-point post-surgery.
The DU123015-treated group recovered from a neurolog-
ical score of 4 to 1 from day 1 to day 14, but this improve-
ment was akin to placebo-treated controls and did not
reach statistical significance. MK-801-treated animals had
a consistently improved neurological outcome at all time-
points (P < 0.05). MK-801 therefore had a beneficial effect
on neurological recovery, whereas DU123015 did not sig-
nificantly alter this outcome.
The T2-weighted MRI scans at 1, 3 and 14 days post MCAo
did also not reveal any protection of brain tissue after
administration of DU123015 (Figure 3E, F(1,19) = 0.078,
n.s.), but rather indicated a slight increase in infarct vol-
ume by 16% ± 26 1 day post-surgery and by 11% ± 32 at
14 days relative to placebo-controls. Cortical only and
striatal only infarct volumes were also assessed for both
DU123015 and placebo-controls. However, this analysis
also revealed no significant differences between cortical
only (F(1,19) = 0.076, P = 0.786) and striatal only (F(1,19) =
0.317, P = 0.580) lesion volumes of DU123015 treated
animals when compared to controls. In contrast, MK-801
consistently decreased lesion volume at all time points
(Figure 3F, F(1,8) = 10.179, P < 0.05). This decrease in
lesion volume was substantial and resulted in a 67% ± 11
decrease in lesion volume on day 1, 66% ± 8 reduction on
day 3 and a final reduction of 80% ± 13 at day 14 relative
to placebo-controls. This demonstrates that the therapeu-
tic effect of MK-801 is persisting and increasing over at
least 2 weeks. MK-801 therefore is efficacious in this
model, whereas DU123015 does not convey neuroprotec-
tion.
To further probe the behavioural significance of a poten-
tial neuroprotectant, the impact of treatment on somato-
sensory function was assessed using the bilateral
asymmetry test (BAT). A GLM repeated measures ANOVA
revealed no overall statistically significant differences in
total time taking for tape removal between DU123015
and glucosaline control-treated groups (Figure 4A, F(1,19)=
1.518, n.s.). A similar observation was evident on the dif-
ference between removing the left or right sticky tape (a
measure of sensorimotor neglect), where DU123015-
treated and control animals performed alike (Figure 4C,
F(1,14)= 0.471). In contrast, MK-801 significantly
improved the animals' behaviour and reduced removal
time by 54% at 14 days. A GLM repeated measures
ANOVA revealed a main effect of group at both 3 and 14
days post-surgery (Figure 4B, F(1,8) = 8.724, P < 0.05). An
even more dramatic effect was evident on the forepaw
asymmetry that was reduced by 73% on day 3 and by 69%
on day 14 (Figure 4D, F(1,8) = 9.214, P < 0.05). Therefore
MK-801 not only exerted an anatomical benefit, but dem-
onstrated a corresponding functional improvement.
Discussion
Pharmacological therapies for stroke aim to provide neu-
roprotection that results in an improved behavioural out-
come. 5HT1A agonists have recently emerged as a potential
new target to promote neuroprotection in stroke. How-
ever, to date very few thorough preclinical examinations
using this class of compounds have been conducted and
we therefore undertook here a systematic study of the
novel 5HT1A agonist, DU123015. Using a variety of tran-
sient focal cerebral ischaemia models that replicate the
pathophysiology of stroke, no significant therapeutic effi-
cacy of DU123015 was detected on structural and behav-
ioural measures. In contrast, MK-801, an NMDA-
antagonist, which served as a positive control significantly
reduced lesion volume and behavioural impairments in 2
of the 3 experiments.
Efficacy of 5HT1A agonists
Oedema corrected MR images, neurological deficit scor-
ing and the Bilateral Asymmetry Test (BAT), all revealed
that DU123015 did not significantly improve outcome in
a mild or severe cortical infarct. Also, the location of the
lesion itself did not affect efficacy, as neither a purely cor-
tical, nor a cortical plus subcortical lesion, bestowed any
efficacy to the 5HT1A agonist. In contrast, MK-801 exerted
significant benefits in all cases, apart from the 120 min
cortical lesion suggesting that this occlusion time is too
severe to observe therapeutic efficacy. The use of hyperten-
sive or normotensive animals also did not affect the struc-
tural or behavioural outcome with DU123015 proving
that no indirect benefit can be gained through an anti-
hypertensive effect. Increasing the dose of DU123015
could potentially yield neuroprotection, but physiological
effects of higher doses on temperature and blood pressure
could be the main mediators of lesion attenuation at these
doses. Previous studies using similar doses as those
reported here have indeed observed a therapeutic benefit
of 5HT1A agonists in cell culture [8,19], models of trau-
matic brain injury [17], and permanent occlusion models
of ischaemia [9,20-23].
To ensure a very thorough assessment of treatment effi-
cacy, we used here a multi-modal assessment that
included structural and behavioural measures that are
interdependent [13]. To date, only a few studies [11,12]Page 8 of 12
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Neuroprotective efficacy of 5HT1A agonist DU123015 and positive control MK-801 in the 90 minutes Intra-Luminal Tread (ILT) model of MCAoFig re 3
Neuroprotective efficacy of 5HT1A agonist DU123015 and positive control MK-801 in the 90 minutes Intra-
Luminal Tread (ILT) model of MCAo. The body weights of animals treated with DU123015 (A) and MK-801 (B). (C) No 
significant differences were observed on neurological functions in animals treated with DU123015 (D) A Kruskall-Wallis non-
parametric test indicated that MK-801 improved neurological functions impaired by stroke. (E) No significant differences were 
observed on oedema corrected MRI lesion volume for DU123015-treated animals. (F) In contrast, MK-801 significantly 
reduced lesion volume at all time points (*) P < 0.05 (**) P < 0.01.
DU123015
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
230
280
330
380 Placebo
DU123015
Time-points (days)
Bo
dy
 w
ei
gh
t (
g)
MK-801
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
230
280
330
380 PlaceboMK-801
Time-points (days)
Bo
dy
 w
ei
gh
t (
g)
plac DU123015 Plac DU123015 Plac DU123015
0
1
2
3
4
5
6
7
Day 1 Day 7 Day 14
Ne
u
ro
lo
gi
ca
l S
co
re
Plac MK-801 Plac MK-801 Plac MK-801
0
1
2
3
4
5
6
7
Day 1 Day 7 Day 14
Ne
u
ro
lo
gi
ca
l S
co
re
1 3 14
0
25
50
75
100
125
150 DU123015
Placebo
Time-points (days)
%
 in
fa
rc
t v
o
lu
m
e
Intra-luminal Thread
1 3 14
0
25
50
75
100
125
150 MK-801
Placebo
*
*
*
*
Time-points (days)
%
 in
fa
rc
t v
o
lu
m
e
M
R
I
N
eu
ro
lo
gi
ca
l S
co
re
Bo
dy
 w
ei
gh
t
BMC Neuroscience 2009, 10:82 http://www.biomedcentral.com/1471-2202/10/82have reported significant treatment effects 5HT1A agonists
in stroke, but these mainly relied on a single outcome
measure. In contrast, the present series of experiments
provides a strong indication that the 5HT1A agonist
DU123015 at this dose does not promote significant
structural, neurological or behavioural improvements in
stroke.
Although the pharmacological characteristics of
DU123015 are comparable to Repinotan, the recent fail-
ure of Repinotan in a phase II, randomized, double blind
clinical stroke study has provided some uncertainty as to
the reliability and predictability of some of these earlier
pre-clinical studies [24]. No improvement in behavioural
or neurological outcomes was evident when patients were
treated with Repinotan compared to placebo. Our results
here are in line with these clinical observations that our
5HT1A agonist did not affect the anatomical, behavioural
and neurological outcomes after stroke.
Assessing neuroprotection in stroke
The failure of over 700 potential neuroprotective com-
pounds which have been successful in pre-clinical studies
has prompted the development of more rigorous guide-
lines for future pre-clinical and clinical stroke trials. How-
ever, the recent failure of the most promising compound
for the treatment of ischaemic stroke, NXY-059 [25], a free
radical scavenging agent, has led to the stipulation that
more stringent conceptual and methodological issues
must be adopted in order to produce successful neuropro-
tective compounds [26]. For example, testing in two mod-
els of focal ischaemia (varying durations of ischaemia) in
different strains of rats should be reported using stringent
inclusion/exclusion criteria and outcome measures
assessed at acute and chronic time-points using objective
in-vivo approaches. This method of evaluating potential
neuroprotective compounds will minimise the translation
of less efficacious compounds and provide a more thor-
ough pre-clinical evaluation of putative therapeutic agents
Bilateral Asymmetry Test (BAT) for 90 minutes intra-luminal thread model of MCAoF gure 4
Bilateral Asymmetry Test (BAT) for 90 minutes intra-luminal thread model of MCAo. DU123015 did not 
improve the total time taken to remove sticky tape from forepaws (A), whereas MK-801 did significantly improved outcome 
(B) Difference between removal of the sticky tape from the right and left forepaws (L-R) did not improve with DU123015 
treatment (C), whereas MK-801 did (D).
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pound validates the models, experimental methods and
outcome measures each time [27]. We here utilized Dizol-
cilpine (MK-801) as a positive control due to extensively
documented therapeutic effects of this compound in
experimental stroke [18,28-30] and other studies previ-
ously also included this compound as a positive control
[28,31,32]. Inclusion of the positive reference compound
and its lack of efficacy in a severe cortical lesion here there-
fore allowed us to establish that any neuroprotection that
could be seen under these conditions would indeed have
been very significant, while at the same time providing us
with evidence that a standard neuroprotection was achiev-
able under the other conditions.
Establishing efficacy, however, is also dependent on strin-
gent outcome measures. The interdependence of different
measures is an important aspect to corroborate outcome
measures within a single experiment. We previously
reported a highly significant correlation of MRI lesion vol-
ume with neurological score and the BAT in the cortical
infarct model but there was a less significant correlation
between neurological score and the BAT [13]. The MRI
outcome measure in this study was also the most consist-
ent measure in terms of variability and hence provided a
more reliable measure to detect group differences in the
distal MCAo model. Notably, MK-801 decreased neuro-
logical deficit after mild ischaemic damage, but the high
variability of neurological deficit in the control group lim-
ited our ability to detect a significant group difference,
although a clear statistical difference could be detected
from the MRI. In the ILT model, however, MK-801 signif-
icantly reduced both the neurological deficits and lesion
volume demonstrating the reliability and sensitivity of
both measures to detect a significant treatment effect. In
contrast, the 5HT1A agonist lacked efficacy on any test,
clearly indicating a lack of significant efficacy. The inher-
ent variability in neurological tests may render this assess-
ment modality less sensitive to neuroprotection
compared to MRI, but neurological deficits, as well as
behavioural tests measure aspects of the damage that are
not completely predicted by structural measures. Never-
theless, these functional facets need to be included in pre-
clinical studies to highlight primary clinical outcome
measures that might not be entirely captured by anatomi-
cal assessments.
Conclusion
This study has revealed that the 5HT1A agonist DU123015
was not efficacious on any outcome measure that was
examined in this investigation. Our study also suggests a
more rigorous approach to neuroprotection studies,
which provides detailed evidence of the lack of neuropro-
tective efficacy of DU123015 in many different circum-
stances. We believe the publication of neuroprotection
studies producing negative or neutral results is a vital
aspect of screening novel compounds and drug targets.
These are a necessary addition to the literature to establish
the clinical potential of a class of agents [33]. Future
guidelines for the screening of potential neuroprotective
compounds and avoidance of false positives may benefit
from further methodological advances as exemplified in
this study.
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